Genetic Mutations Could Predict Patients Likely to Benefit from New Class of Cancer Drugs

Genetic Mutations Could Predict Patients Likely to Benefit from New Class of Cancer Drugs
Testing for mutations in ARID1A, a gene that is commonly mutated in ovarian cancers, may help predict which patients are likely to respond to a novel class of drugs currently in clinical development, new research found. The study, “ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A,” published in Nature Communications, shows

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Tagged , , , .

Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.

Leave a Comment

Your email address will not be published. Required fields are marked *